$80
Peptides
Retatrutide
Retatrutide (LY3437943). Supplied as a lyophilised powder in 10mg, 20mg, 30mg and 60mg vials.
Supplied as lyophilised powder in 10mg, 20mg, 30mg, 60mg specifications. Storage: -20°C · keep dry · avoid light. Dispatched from Sydney, Australia-wide.
Product information
About Retatrutide
Retatrutide (LY3437943)
Research background as published in the scientific literature. Supplied for in-vitro laboratory research only; nothing here is a claim about use in humans or animals.
Retatrutide (developmental code LY3437943) is a synthetic single-molecule agonist that acts at three incretin-related receptors — the GLP-1, GIP, and glucagon receptors. This combination distinguishes it from single-agonist (GLP-1) and dual-agonist (GLP-1 / GIP) research peptides.
It is an investigational compound that appears in a body of preclinical and clinical scientific literature examining incretin and glucagon receptor signalling. Quantified Peptides supplies Retatrutide strictly as a reference material for laboratory research and makes no representation regarding its use in humans or animals.
- Class
- GGG triple receptor agonist
- Targets
- GLP-1 · GIP · glucagon receptors
- Form
- Lyophilised powder
- Developmental code
- LY3437943
- Receptors
- GLP-1 · GIP · glucagon
- Mechanism class
- Triple incretin agonist
- Research models
- Metabolic / receptor studies
- Primary research
- Incretin receptor signalling
Also in this range.
Compounds the supplier files alongside this one.
